Chemotherapeutic Targeting of Cancer-Induced Immunosuppressive Cells

Darya Alizadeh¹ and Nicolas Larmonier¹,²

Abstract

The expansion of immunosuppressive cells represents a cardinal strategy deployed by tumors to escape from detection and elimination by the immune system. Regulatory T lymphocytes (Treg) and myeloid-derived suppressor cells (MDSC), major components of these inhibitory cellular networks, have drawn intense scrutiny in recent years. In patients with cancer and in animal tumor models, these suppressor cells accumulate in the tumor microenvironment, secondary lymphoid tissues, and in the blood. Equipped with the ability to suppress innate and adaptive anticancer immunity, these cells also foster disease development by promoting tumor neoangiogenesis and by enhancing cancer metastasis. They therefore represent major impediments for anticancer therapies, particularly for immune-based interventions. Recent work has provided evidence that beyond their direct cytotoxic or cytostatic effects on cancer cells, several conventional chemotherapeutic drugs and agents used in targeted therapies can promote the elimination or inactivation of suppressive Tregs or MDSCs, resulting in enhanced antitumor immunity. We analyze findings pertinent to this concept, discuss the possible molecular bases underlying the selective targeting of these immunosuppressive cells by antineoplastic agents, and consider current challenges and future prospects related to the integration of these molecules into more efficient anticancer chemoinmunotherapeutic strategies. Cancer Res; 74(10); 2663–8. ©2014 AACR.
and their efficacy is limited by the emergence of drug-resistant tumor cell clones (6). With the growing understanding of cancer cell biology at the molecular level, more specific antineoplastic agents were developed and referred to as targeted therapeutic agents (6, 7). Typically, molecular-targeted therapies are designed to inhibit oncogenic pathways essential for the proliferation and survival of tumor cells. This approach has sparked considerable hope and has led to the development of many small-molecule inhibitors, with imatinib mesylate, a BCR-ABL tyrosine kinase inhibitor (TKI), as an archetype (6). The therapeutic efficacy of these molecules as single agents is, however, limited by the acquisition of secondary mutations, leading to drug-resistant tumor clones and patient relapse.

Recent studies have lent support to the notion that the antitumoral efficacy of many chemotherapeutic drugs or targeted agents may be partially or substantially mediated by immune-dependent mechanisms (6). For instance, the promotion of anticancer immune responses by anthracyclines has been related to the induction of an immunogenic type of tumor cell death associated with immune-activating "danger" signals. This fosters the antigen processing and presenting function of DCs (responsible for the initiation and regulation of immune responses), leading to enhanced priming and activation of tumor-specific T lymphocytes. Several anticancer agents (for instance, platinum-based molecules, alkylating agents, anthracyclines, or nucleoside analogues) are also capable of enhancing the proliferation and function of antitumoral CTL, natural killer (NK), and Th cells (6). In addition, drugs such as doxorubicin or cisplatin may sensitize tumor cells to CTL-mediated killing. Cisplatin has also recently been shown to promote the accumulation of CD11c⁺ DC in the tumor beds, which after intratumoral delivery of tumor antigens are capable to induce tumor-specific CTLs (8). The aforementioned immunomodulatory effects of antineoplastic agents have been extensively reviewed elsewhere (6). Evidence has emerged that these molecules may also enhance anticancer immunity by blocking immunoinhibitory cellular networks (Fig. 1). In the current review, we examine this concept, focusing on two major immunosuppressive cell populations, Tregs and MDSCs. The possible molecular mechanisms underlying the selective targeting of these suppressive cells and the prospect of exploiting the multifaceted properties of anticancer agents in more efficient chemoimmunotherapeutic strategies are discussed.

Targeting Tregs and MDSCs Using Antineoplastic Agents

**Treg elimination or inactivation**

CD4⁺CD25⁺ Tregs represent a subpopulation of T cells characterized by the expression of FoxP3, a forkhead/winged helix transcription factor essential for their development and function. Tregs control immune responses by suppressing conventional effector T lymphocytes, NK, DCs or macrophages through different mechanisms (9). Tregs are produced during T-cell development in the thymus or are generated in the periphery from naïve CD4⁺ T lymphocytes. Compelling studies in mice and human have demonstrated that many cancers can induce the proliferation of Tregs and/or promote their generation from naïve T cells, resulting in the accumulation of these cells in the tumor beds and in the periphery (5). Importantly, the elimination and/or functional inactivation of tumor-induced Tregs can promote antitumor immunity and enhance the efficacy of immunotherapy.

**Treg targeting using chemotherapeutic drugs.** Cyclophosphamide (an alkylating agent used to treat some lymphoma, leukemia, multiple myeloma, neuroblastoma, or breast or ovarian cancers) was one of the first drugs reported for its ability to interfere with suppressive T cells and to improve immunotherapy (10). We demonstrated in a rat colon cancer model that cyclophosphamide eliminates CD4⁺CD25⁺ Tregs and improves overall survival when combined with immunotherapy (11). However, in this model, cyclophosphamide administration results in a nonselective elimination of both suppressor and effector T cells. Of therapeutic relevance, effector T lymphocytes reconstitute earlier than Tregs and for a defined window of time, low Treg to effector CD4⁺ and CD8⁺ T lymphocyte ratios allow efficient immunotherapy (11). A later report indicated that low-dose cyclophosphamide triggers mouse Treg apoptosis in vitro and in vivo without affecting conventional CD4⁺CD25⁺ T-cell viability. In this study, cyclophosphamide also impairs Treg-suppressive function by down-regulating FoxP3 and glucocorticoid-induced TNFR-related protein (12). The possibility of combining cyclophosphamide-mediated elimination of Tregs with tumor-specific vaccination was further confirmed in different mouse models (13). Interestingly, the association of this drug with an agonistic antibody against the costimulatory receptor OX40 was shown to eliminate intratumoral, but not peripheral, Tregs (14). Along these lines, cyclophosphamide was proven effective in reducing Treg number and restoring T and NK cell effector functions in patients with different types of advanced stage cancers (15). The mechanism(s) behind the preferential elimination of Tregs by cyclophosphamide remain to be fully elucidated. Because this alkylating agent primarily affects highly proliferative cells, it is possible that the higher proliferation rate of Tregs (as compared with other cells) in the context of growing tumor makes them ideal targets. Similarly, the preferential depletion of intratumoral Tregs (as opposed to peripheral Tregs) observed in some studies may reflect differential characteristics of Tregs (such as their proliferation status) depending on their location. It should also be underlined that in most studies, the immunostimulatory effects of cyclophosphamide were observed only at low, "metronomic" doses, whereas at high doses, this drug is immunosuppressive. In addition, cyclophosphamide-mediated depletion of Tregs is usually transient and a new Treg pool, with antigen recognition specificities skewed toward cancer antigens, eventually reconstitutes, mainly as a result of tumor-driven conversion of CD4⁺CD25⁺ FoxP3⁻ T cells (5). Therefore, in a chemoimmunotherapeutic perspective, careful considerations should be given to the dosing of this agent and to the timing of immunotherapy performed post-cyclophosphamide administration. These parameters are still in need of further optimization.

Paclitaxel, a mitotic inhibitor, has been reported to selectively reduce Treg number and function while sparing effector T lymphocytes in patients with advanced non–small cell lung
The selective induction of Treg apoptosis by paclitaxel was attributed to the upregulation of the cell death receptor Fas on Tregs but not on effector cells (16). In a mouse lung carcinoma model, paclitaxel was shown to induce Treg but not effector cell apoptosis, possibly by selectively inducing the downregulation of the antiapoptotic molecule Bcl-2 and the upregulation of Bax (a proapoptotic factor; ref. 17). The anticancer molecules, lenalidomide and pomalidomide, may also alter Treg proliferation and function by reducing FoxP3 expression through unclear molecular mechanisms (18). Lenalidomide has also recently been shown to reduce both Treg and MDSC number in the A20 lymphoma model (19). In addition, low-dose metronomic regimens of temozolomide, an alkylating agent, can reduce Treg to total CD4+ T-lymphocyte ratios and impair Treg-suppressive activity in glioma-bearing rats (20). Importantly, high doses of this agent have no effect on Tregs, further underlining that chemotherapeutic drugs exert distinct immunomodulatory effects depending on their concentration. Temozolomide has also been reported to specifically reduce Tregs in advanced melanoma patients (21).

**Influence of agents used in targeted therapies on Tregs.**

Several TKIs have been described for their ability to impair Tregs. Sunitinib, a multityrosine kinase inhibitor, has been reported to decrease the number of peripheral and tumor-infiltrating Tregs in patients with renal cell carcinoma (RCC; ref. 22). Sunitinib also reduces Tregs in the mouse CT26 tumor model through targeting of the VEGF-VEGFR axis (23). Similar effects of the multikinase inhibitor sorafenib on Tregs were observed (24). We have reported that imatinib mesylate (a BCR-ABL TKI, which also blocks c-KIT, a oncogenic tyrosine kinase) can reduce Treg numbers in the mouse CT26 model (25). These data suggest that the targeting of specific kinases could be a potential strategy to reduce Treg numbers in advanced cancers.
kinase receptor and platelet-derived growth factor receptor) reduces Treg number, impairs their suppressive function, and promotes the efficacy of dendritic cell-based vaccination in a lymphoma mouse model (25). Imatinib interferes with early TCR/CD28 signaling events, leading to the downregulation of FoxP3. In line with this result, it has recently been demonstrated that dasatinib (a second-generation TKI used against imatinib-resistant leukemia and malignancies characterized by c-KIT mutations) decreases the frequency of circulating Tregs in a mastocytoma mouse model (26). Importantly, the reduction of Treg number was transient and these cells reconstituted quickly after drug removal. In this study, dasatinib efficiently synergizes with immunotherapy (agonistic anti-OX40), resulting in improved antitumor effects (26). The increased sensitivity of Tregs to imatinib and dasatinib compared with effector T cells may be explained by a higher dependence of Tregs on Lck, an essential tyrosine kinase in TCR signaling, and potential target of these TKI.

The apparent ability of the aforementioned antineoplastic agents to affect multiple immunologic processes has sparked some criticism as it relates to their usefulness as direct Treg-targeting agents. Whether the improvement of anticancer immunity may result from Treg depletion or from the concomitant enhancement of effector immune cell function by these molecules remains indeed difficult to ascertain. A more refined identification of the molecular bases underlying the mode of action of these agents on Tregs will certainly help to address this issue. Nonetheless, although antibody-based approaches such as anti-CTLA4 or anti-OX40 have shown promise to impair Tregs, a universal optimized strategy to selectively target these cells is still needed. In this context, the possibility of using conventional chemotherapeutic molecules or targeted therapeutic agents to interfere with these immunosuppressive lymphocytes remains an appealing strategy.

**MDSC elimination, inactivation, and/or differentiation into proinflammatory cells**

MDSCs have been described as a heterogeneous population of immature myeloid cells endowed with the capacity to inhibit innate and adaptive immunity (4). In mice, two main populations equipped with dedicated mechanisms of suppression and functions can be distinguished: monocytic CD11b+Ly6G−Ly6Chi and granulocytic CD11b+Ly6G−Ly6Clow MDSCs (4). Typically, solid tumors mainly induce the expansion of the granulocytic subset. Human MDSCs are primarily defined by a CD33+CD11b+HLA-DRlowCD14hi phenotype. The accumulation of these cells in the periphery and tumor microenvironment results from the stimulation of myelopoiesis and from the blockade of the differentiation of immature into mature myeloid cells by several tumor-derived factors which also promote MDSC-suppressive function (4). Multiple studies conducted in rodents and patients with different types of cancer have demonstrated that MDSC elimination, inhibition, or the induction of their differentiation into proinflammatory cells using anticancer agents enhance antitumor immunity and foster the response to immunotherapy.

**Targeting MDSCs with conventional chemotherapeutic drugs.** Gemcitabine, an antimetabolite drug (nucleoside analogue), used for the treatment of pancreatic, breast, ovarian, and lung cancers, has been reported to deplete MDSCs in tumor-bearing mice, resulting in enhanced antitumor immunity (27). Another antimetabolite, 5-fluorouracil, used at low doses, has also been shown to induce MDSC apoptosis (27). Interestingly, MDSCs are more sensitive to these molecules than other immune cells or than tumor cells. This selective effect was explained by a lower expression of thymidylate synthase by MDSCs (27). The DNA-demethylating agent 5-azacytidine may also reduce the accumulation and function of MDSCs induced in the mouse TC-1/A9 and TRAMP-C2 tumor models (28). Docetaxel, (a mitotic inhibitor, semisynthetic analogue of paclitaxel) was shown to impair MDSC-suppressive function, predominantly by blocking Stat3 phosphorylation and by promoting MDSC differentiation into M1 macrophages (29). Similarly, it has also been reported that low-dose paclitaxel promotes MDSC differentiation into dendritic cells *in vitro* (30).

The anthracycline doxorubicin has been described for its plethoric immunostimulatory effects (6). We have recently demonstrated in different mouse cancer models that this drug selectively, but however transiently, eliminates and inactivates MDSCs (31). This preferential targeting of MDSCs translates into increased effector lymphocyte to immunosuppressive MDSC ratios and is associated with enhanced CD4+ and CD8+, and NK cell activation and proinflammatory cytokine production, fundamental prerequisites to efficient immunotherapy. A chemoimmunotherapeutic regimen consisting of doxorubicin and adoptive transfer of CD4+ Th lymphocytes impairs tumor development, metastatic spreading, and improves survival. It is noteworthy that MDSC number remains low over time in animals receiving the combination treatment, whereas these cells expanded *de novo* posttherapy in mice administered with doxorubicin alone. This observation further underlines the possibility, and importance, of combining chemotherapeutic approaches with immunostimulation (31). The selective effect of doxorubicin may again be partly explained by the preferential targeting of highly proliferative cells (in untreated tumor-bearing mice, MDSC proliferation status is higher than that of T or NK cells). Another possibility is that doxorubicin may enhance the already high production of reactive oxygen species (ROS) by MDSCs (compared with other cell subsets), leading to ROS-dependent apoptosis.

**Impact of molecules used in targeted therapies on tumor-induced MDSCs.** Sunitinib, has been shown to reduce circulating MDSC number and suppressive function in patients with RCC, which correlates with improved T-cell function (32). Again, this effect was selective because T cells exposed to concentrations of sunitinib that impair MDSCs were viable and functional. Although the molecular mechanisms remain to be fully deciphered, it has been speculated that this agent, known to interfere with tyrosine kinases of the VGEF1-3 or c-KIT family, may inhibit VEGF and/or c-KIT–mediating signaling in MDSCs, pathways that participate in the tumor-driven expansion of these cells (32, 33). An additional mode of action of sunitinib may include Stat3 inhibition (34). Because stem-cell factor (c-KIT ligand) contributes to MDSC accumulation, one should expect that other c-KIT–targeting TKI such as...
dASATINH, IMATINH, OR SUNITINH MAY ALSO EFFECTIVELY INTERFERE WITH THIS SUPPRESSIVE CELL POPULATION.

RETICENCES RAISED BY THE ABSENCE OF DEFINITIVE MECHANISTIC GROUNDS EXPLAINING THE SELECTIVITY OF ANTI NEOPLASTIC AGENTS ON MDSCS HAVE ERODED THE EXPLOITATION OF THIS IMMUNOMODULATORY STRATEGY. IN ADDITION, MDSC ELIMINATION WITH THESE MOLECULES IS, AS FOR TREGS, USUALLY TRANSIENT AND A NARROW THERAPEUTIC WINDOW IS AVAILABLE FOR IMMUNOSTIMULATORY INTERVENTIONS. MANY PATHWAYS INVOLVED IN MDSC GENERATION AND SUPPRESSIVE ACTIVITY CAN BE TARGETED WITH SEVERAL OTHER INHIBITORS SUCH AS CELECOXIB (COX-2 INHIBITOR) OR SILDENAFIL (PHOSPHODIESTERASE-5 INHIBITOR). A SYSTEMATIC COMPARISON OF THE EFFICACY OF THESE REAGENTS WITH THAT OF LOW NONTOXIC DOSES OF ANTI NEOPLASTIC AGENTS TO IMPACT THE MULTIPLE ASPECTS OF MDSC IMMUNOLOGY IS UNDERINTELLIGIBLY NEEDED.

FUTURE DIRECTIONS AND CONCLUDING REMARKS

THE DISCOVERY THAT MANY CONVENTIONAL CHEMOTHERAPEUTIC DRUGS AND MOLECULES USED IN TARGETED THERAPIES CAN BLUNT THE IMMUNOSUPPRESSIVE CELLULAR NETWORKS INDUCED BY TUMORS HAS SPARKED A NEW PROMISING AREA OF RESEARCH, AT THE INTERFACE BETWEEN TRADITIONAL CANCER THERAPIES AND IMMUNE-BASED STRATEGIES. IT IS, HOWEVER, NOTEWORTHY THAT THE LONG-TERM IMMUNOLOGIC CONSEQUENCES OF ANTICANCER AGENT ADMINISTRATION ARE NOT ALWAYS THERAPEUTICALLY BENEFICIAL AND ESSENTIALLY DEPEND ON PARAMETERS SUCH AS THE NATURE OF THE CONSIDERED MOLECULE(S), THE DOSING, AND SCHEDULING, WHICH ALL REQUIRE FURTHER OPTIMIZATION.

IN THIS CONTEXT, THE IDENTIFICATION OF ADDITIONAL SPECIFIC ANTICANCER AGENTS ENDOWED WITH THE ABILITY TO IMPED SUPPRESSIVE CELLS SUCH AS TREGS AND MDSCS WHILE SPARING (OR PROMOTING) ANTITUMOR IMMUNE EFFECTORS IS OF PARAMOUNT IMPORTANCE. ALONG THESE LINES, A MORE REFINED UNDERSTANDING OF THE INTERFERENCE(S) OF THESE COMPOUNDS WITH SPECIFIC MOLECULAR PATHWAYS IN SUPPRESSIVE CELLS SHOULD HELP DECIPHER THE MECHANISMS UNDERLYING THE SELECTIVE TARGETING OF THESE CELLS. IT SHOULD ALSO BE UNDERLINED THAT IN MOST CASES, ANTI NEOPLASTIC MOLECULES ONLY CURTAIL SUPPRESSIVE CELLS FOR A TRANSIENT PERIOD OF TIME. THIS IMPOSES A REGULAR MONITORING TO IDENTIFY A SPECIFIC WINDOW OF TIME ASSOCIATED WITH HIGH EFFECTOR TO SUPPRESSOR RATIOS, PERMISSIVE FOR EFFICIENT IMMUNOTHERAPEUTIC INTERVENTIONS. CONCEIVABLY, AS DIFFERENT MOLECULES MAY AFFECT DIFFERENT SUPPRESSIVE CELL POPULATIONS (FOR INSTANCE, CYCLOPHOSPHAMIDE PRIMARILY TARGETS TREGS, WHEREAS DOXORUBICIN MAINLY IMPACTS MDSCS), THE IDENTIFICATION OF THE IMMUNOHIBITORY CELL SUBSET PREDOMINANTLY EXPANDED IN A CONSIDERED CANCER PATIENT SHOULD GUIDE THE CHOICE OF THE OPTIMAL AGENT(S).

AN ADDITIONAL IMPORTANT QUESTION RELATES TO THE NOTION OF TREG "REPROGRAMMING." THE PLASTICITY OF FOXP3+ TREGS AND THE POSSIBILITY TO INDUCE THEIR TRANS-DIFFERENTIATION INTO EFFECTOR NONSUPPRESSIVE CELLS SUCH AS TH17 HAVE BEEN DESCRIBED (35). ALTHOUGH A RECENT STUDY HAS INDICATED THAT CYCLOPHOSPHAMIDE-INDUCED GENERATION OF TH17 DOES NOT DEPEND ON TREG REPROGRAMMING (36), THE POSSIBILITY THAT OTHER AGENTS MAY FOSTER THE CONVERSION OF ALREADY POLARIZED TREGS INTO EFFECTOR SUBSETS, OR REROUTE THE DIFFERENTIATION OF NAÏVE T CELLS TOWARD EFFECTOR T LYMPHOCYTES INSTEAD OF TREGS REMAINS TO BE ADDRESSED.

A SIGNIFICANT ADVANCE IN OUR UNDERSTANDING OF THE PLETHORIC IMMUNOMODULATORY PROPERTIES OF MANY CONVENTIONAL CHEMOTHERAPEUTIC DRUGS AND TARGETED THERAPEUTIC AGENTS HAS BEEN A DRIVING FORCE BEHIND THE DESIGN AND DEVELOPMENT OF CHEMIMUNOTHERAPEUTIC STRATEGIES. SELECTED ANTI NEOPLASTIC AGENTS, BY INDUCING RAPID TUMOR SHRINKAGE, REVERSING CANCER-INDUCED IMMUNOSUPPRESSION, AND PROMOTING ANTITUMOR CYTOTOXIC IMMUNE EFFECTORS MAY CREATE A FAVORABLE ENVIRONMENT, ALLOWING IMMUNE-BASED THERAPIES TO ELCIT LONG-LASTING MEMORY IMMUNE RESPONSES CAPABLE OF CONTROLLING RELAPSE DUE TO DRUG-RESISTANT DISEASE AND METASTATIC SPREADING (FIG. 1). ALTHOUGH THE DOSE FOR EACH THERAPEUTIC ARM AND THE SEQUENCE OF ADMINISTRATION REQUIRE ADDITIONAL REFINEMENTS, THE COMBINATION OF THESE TWO MODALITIES, OPERATING BY DISTINCT BUT COMPLEMENTARY AND OVERLAPPING MECHANISMS, REPRESENTS ARGUABLY A PROMISING EMERGING ANTICANCER STRATEGY.

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

NO POTENTIAL CONFLICTS OF INTEREST WERE DISCLOSED.

ACKNOWLEDGMENTS

WE APOLOGIZE TO ALL THE AUTHORS Whose WORK COULD NOT BE CITED DUE TO SPACE LIMITATION.

GRANT SUPPORT

THIS WORK WAS SUPPORTED, IN PART, BY THE CANCER BIOLOGY TRAINING GRANT T32CA009213, AZ CANCER CENTER SUPPORT GRANT CA023074, AND NIH GRANT R01 CA104926.

Received January 31, 2014; revised March 19, 2014; accepted March 20, 2014; published OnlineFirst April 28, 2014.

REFERENCES


Chemotherapeutic Targeting of Cancer-Induced Immunosuppressive Cells

Darya Alizadeh and Nicolas Larmonier


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-14-0301

Cited articles
This article cites 35 articles, 15 of which you can access for free at:
http://cancerres.aacrjournals.org/content/74/10/2663.full#ref-list-1

Citing articles
This article has been cited by 7 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/74/10/2663.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.